Abstract
Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Update on Aurora Kinase Inhibitors in Gynecologic Malignancies
Volume: 3 Issue: 3
Author(s): Xia Tao, Hye S. Chon, Siqing Fu, John J. Kavanagh and Wei Hu
Affiliation:
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Abstract: Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Export Options
About this article
Cite this article as:
Tao Xia, Chon S. Hye, Fu Siqing, Kavanagh J. John and Hu Wei, Update on Aurora Kinase Inhibitors in Gynecologic Malignancies, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242322
DOI https://dx.doi.org/10.2174/157489208786242322 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fentanyl for Breakthrough Cancer Pain: Where are We?
Reviews on Recent Clinical Trials Phospholipid Nanosomes
Current Drug Delivery Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design Recent Patents on Influenza Vaccines
Recent Patents on Biotechnology MicroRNA Dysregulation in Esophageal Neoplasia: The Biological Rationale for Novel Therapeutic Options
Current Pharmaceutical Design Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials
Anti-Cancer Agents in Medicinal Chemistry Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Molecular Targets for Papillomavirus Therapy
Current Drug Targets - Infectious Disorders Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Boron Containing Macromolecules and Nanovehicles as Delivery Agents for Neutron Capture Therapy†
Anti-Cancer Agents in Medicinal Chemistry Towards Second Generation Hypericin Based Photosensitizers for Photodynamic Therapy
Current Organic Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets A Computational Study of Three Frequent Mutations of EGFR and their Effects on Protein Dimer Formation and Non-Small Cell Lung Cancer Drug Resistance
Current Bioinformatics